971 related articles for article (PubMed ID: 28165883)
1. The role of IL 23 in the treatment of psoriasis.
Puig L
Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
[TBL] [Abstract][Full Text] [Related]
2. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
Kivelevitch DN; Menter A
Immunotherapy; 2015; 7(4):323-33. PubMed ID: 25917624
[TBL] [Abstract][Full Text] [Related]
3. A safety evaluation of guselkumab for the treatment of psoriasis.
Galluzzo M; D'Adamio S; Campione E; Bianchi L; Talamonti M
Expert Opin Drug Saf; 2018 Jul; 17(7):741-751. PubMed ID: 29897790
[TBL] [Abstract][Full Text] [Related]
4. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
5. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.
Torres T
Drugs; 2017 Sep; 77(14):1493-1503. PubMed ID: 28770513
[TBL] [Abstract][Full Text] [Related]
6. Tildrakizumab for treating psoriasis.
Galluzzo M; D'adamio S; Bianchi L; Talamonti M
Expert Opin Biol Ther; 2017 May; 17(5):645-657. PubMed ID: 28271735
[TBL] [Abstract][Full Text] [Related]
7. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
Toussirot E
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):159-68. PubMed ID: 22280236
[TBL] [Abstract][Full Text] [Related]
8. Cytokine-based therapy in psoriasis.
Mitra A; Fallen RS; Lima HC
Clin Rev Allergy Immunol; 2013 Apr; 44(2):173-82. PubMed ID: 22426927
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
Mease PJ
Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
[TBL] [Abstract][Full Text] [Related]
10. Rationale and early clinical data on IL-17 blockade in psoriasis.
Nwe SM; Champlain AH; Gordon KB
Expert Rev Clin Immunol; 2013 Jul; 9(7):677-82. PubMed ID: 23899238
[TBL] [Abstract][Full Text] [Related]
11. The role of IL-17 in psoriasis.
Malakouti M; Brown GE; Wang E; Koo J; Levin EC
J Dermatolog Treat; 2015 Feb; 26(1):41-4. PubMed ID: 24552504
[TBL] [Abstract][Full Text] [Related]
12. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?
Chiricozzi A; Saraceno R; Chimenti MS; Guttman-Yassky E; Krueger JG
Expert Opin Ther Targets; 2014 May; 18(5):513-25. PubMed ID: 24568095
[TBL] [Abstract][Full Text] [Related]
13. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.
Zaghi D; Krueger GG; Callis Duffin K
J Drugs Dermatol; 2012 Feb; 11(2):160-7. PubMed ID: 22270196
[TBL] [Abstract][Full Text] [Related]
14. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
[TBL] [Abstract][Full Text] [Related]
15. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.
Boehncke WH; Brembilla NC; Nissen MJ
Expert Rev Clin Immunol; 2021 Jan; 17(1):5-13. PubMed ID: 33251833
[TBL] [Abstract][Full Text] [Related]
16. Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
Alunno A; Carubbi F; Cafaro G; Pucci G; Battista F; Bartoloni E; Giacomelli R; Schillaci G; Gerli R
Expert Opin Biol Ther; 2015; 15(12):1727-37. PubMed ID: 26653110
[TBL] [Abstract][Full Text] [Related]
17. Risankizumab for the treatment of moderate to severe psoriasis.
Chiricozzi A; Antonioli L; Panduri S; Fornai M; Romanelli M; Blandizzi C
Expert Opin Biol Ther; 2019 Jan; 19(1):1-8. PubMed ID: 30462554
[No Abstract] [Full Text] [Related]
18. Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.
Quatresooz P; Hermanns-Lê T; Piérard GE; Humbert P; Delvenne P; Piérard-Franchimont C
J Biomed Biotechnol; 2012; 2012():147413. PubMed ID: 22754278
[TBL] [Abstract][Full Text] [Related]
19. Risankizumab for the treatment of psoriasis.
Gu C; Yang J
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
[No Abstract] [Full Text] [Related]
20. The role of IL-17 in the treatment of psoriatic arthritis.
Lubrano E; Perrotta FM
Expert Rev Clin Immunol; 2017 Aug; 13(8):815-821. PubMed ID: 28485176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]